These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 16622724)

  • 1. Recurrent paralytic ileus associated with strongyloidiasis in a patient with systemic lupus erythematosus.
    Yoshida H; Endo H; Tanaka S; Ishikawa A; Kondo H; Nakamura T
    Mod Rheumatol; 2006; 16(1):44-7. PubMed ID: 16622724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fatal outcome in a patient under immunosuppressant therapy infected with human T-lymphotropic virus type 1 (HTLV-1), cytomegalovirus (CMV) and Strongyloides stercoralis: a case report.
    Ashida C; Kinoshita K; Nozaki Y; Funauchi M
    BMC Infect Dis; 2020 Jul; 20(1):470. PubMed ID: 32615937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage treatment of disseminated strongyloidiasis in an immunocompromised patient: therapy success with subcutaneous ivermectin.
    Moura EB; Maia Mde O; Ghazi M; Amorim FF; Pinhati HM
    Braz J Infect Dis; 2012; 16(5):479-81. PubMed ID: 22975175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disseminated Strongyloides in systemic lupus erythematosus and antiphospholipid antibody syndrome: a case report.
    Rajadhyaksha A; Mehra S; Kawale J
    Int J Rheum Dis; 2012 Dec; 15(6):e159-61. PubMed ID: 23253246
    [No Abstract]   [Full Text] [Related]  

  • 5. [Fulminant strongyloidiasis successfully treated by subcutaneous ivermectin: an autopsy case].
    Takashima N; Yazawa S; Ishihara A; Sugimoto S; Shiomi K; Hiromatsu K; Nakazato M
    Rinsho Shinkeigaku; 2008 Jan; 48(1):30-5. PubMed ID: 18386629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful use of subcutaneous ivermectin for the treatment of
    Zeitler K; Jariwala R; Restrepo-Jaramillo R; Kapadia S; Casanas B; Alrabaa S; Sriaroon C
    BMJ Case Rep; 2018 Jun; 2018():. PubMed ID: 29866667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tuberculosis in systemic lupus erythematosus in an endemic area and the role of isoniazid prophylaxis during corticosteroid therapy.
    Mok MY; Lo Y; Chan TM; Wong WS; Lau CS
    J Rheumatol; 2005 Apr; 32(4):609-15. PubMed ID: 15801014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of human disseminated strongyloidiasis with a parenteral veterinary formulation of ivermectin.
    Marty FM; Lowry CM; Rodriguez M; Milner DA; Pieciak WS; Sinha A; Fleckenstein L; Baden LR
    Clin Infect Dis; 2005 Jul; 41(1):e5-8. PubMed ID: 15937753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case report: Rectal adminstration of ivermectin to a patient with Strongyloides hyperinfection syndrome.
    Tarr PE; Miele PS; Peregoy KS; Smith MA; Neva FA; Lucey DR
    Am J Trop Med Hyg; 2003 Apr; 68(4):453-5. PubMed ID: 12875295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of strongyloides hyperinfection syndrome: a rheumatological point of view.
    Santiago M; Leitão B
    Eur J Intern Med; 2009 Dec; 20(8):744-8. PubMed ID: 19892301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strongyloides stercoralis hyperinfection in systemic lupus erythematosus and the antiphospholipid syndrome.
    Mora CS; Segami MI; Hidalgo JA
    Semin Arthritis Rheum; 2006 Dec; 36(3):135-43. PubMed ID: 16949135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic yield of double-balloon enteroscopy with intestinal juice analysis for intestinal strongyloidiasis.
    Nakamura N; Matsushita M; Tahashi Y; Shimatani M; Aoi K; Yanagawa M; Okazaki K
    Dig Endosc; 2010 Oct; 22(4):370-2. PubMed ID: 21175501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strongyloides hyperinfection in rheumatoid arthritis.
    Das P; Raghu P; Amit Kumar Dinda ; Garg P
    Int J Surg Pathol; 2007 Oct; 15(4):391-2. PubMed ID: 17913948
    [No Abstract]   [Full Text] [Related]  

  • 14. Strongyloides hyperinfection syndrome complications: a case report and review of the literature.
    Najmuddin A; Hadique S; Parker J
    W V Med J; 2012; 108(1):32-8. PubMed ID: 25134190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Strongyloides stercoralis: a puzzling parasite.
    Luvira V; Watthanakulpanich D; Pittisuttithum P
    Int Health; 2014 Dec; 6(4):273-81. PubMed ID: 25173343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [An overview of Strongyloides stercoralis and its infections].
    Ardiç N
    Mikrobiyol Bul; 2009 Jan; 43(1):169-77. PubMed ID: 19334396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of
    Prabha N; Chhabra N
    Indian J Dermatol Venereol Leprol; 2018; 84(6):709-711. PubMed ID: 30207326
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of ivermectin on allergy-type manifestations in occult strongyloidiasis.
    Rampur L; Jariwala SP; Hudes G; Rosenstreich DL; de Vos G
    Ann Allergy Asthma Immunol; 2016 Oct; 117(4):423-428. PubMed ID: 27566864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatal relapse of disseminated strongyloidiasis in an HIV-positive patient, despite ivermectin treatment.
    Mattioni S; Valin N; Cracco C; Thellier M; Danis M; Caumes E
    Ann Trop Med Parasitol; 2008 Dec; 102(8):693-8. PubMed ID: 19000386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disseminated Strongyloides stercoralis infection with a cutaneous presentation in an immunosuppressed patient.
    Benvenuti F; Carrascosa JM; Boada A; Ferrandiz C
    Eur J Dermatol; 2009; 19(4):404-5. PubMed ID: 19467975
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.